<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080741</url>
  </required_header>
  <id_info>
    <org_study_id>CHAUVET-GELINIER APJ 2013</org_study_id>
    <nct_id>NCT02080741</nct_id>
  </id_info>
  <brief_title>STUDY IN LEUCOCYTES FROM PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES GENETIC MARKERS OF INFLAMMATION AND OXIDATIVE STRESS (TÉLOMÈRES/ CANDIDATE GENES) ACCORDING TO THE TYPE A OR TYPE B BEHAVIOUR PROFILE</brief_title>
  <acronym>Diatolepsy</acronym>
  <official_title>STUDY IN LEUCOCYTES FROM PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES GENETIC MARKERS OF INFLAMMATION AND OXIDATIVE STRESS (TÉLOMÈRES/ CANDIDATE GENES) ACCORDING TO THE TYPE A OR TYPE B BEHAVIOUR PROFILE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of
      50 patients according to their behaviour type, and their adaptation to different factors of
      stress encountered in their lives:

        -  the first group will consist of patients with a characteristic Type A behaviour
           profile, that is to say patients with a &quot;proactive, impatient&quot; behaviour pattern

        -  the second group will consist of patients with a characteristic Type B behaviour
           profile that is to say patients with a &quot;calm, slow&quot; behaviour pattern The objective is
           to know if the different behaviour patterns are associated with distinct biological
           markers likely to influence the evolution of the diabetes.

      Participation in this study will be approximately 1h30, patients will participate ONCE ONLY:

        1. they will answer simple questions about their disease and then complete 3
           questionnaires each with 14 items.

        2. they will meet a clinical psychologist for an interview lasting approximately 45
           minutes recorded on an audio recorder. The consultation will be used to seek links
           between the psyche and the disease.

        3. they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the
           morning.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Telomere length</measure>
    <time_frame>Baselines</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of expression of candidate genes</measure>
    <time_frame>Baselines</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Complications of diabetes (Nephropathy, Retinopathy, Neuropathy, Coronaropathy)</measure>
    <time_frame>Baselines</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Scores on psychiatric/psychological scales</measure>
    <time_frame>Baselines</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of the specific psychological interview EMIC</measure>
    <time_frame>Baselines</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Type 1 or Type 2 Diabetes</condition>
  <condition>Patients With a Type A or B Behaviour Profile</condition>
  <arm_group>
    <arm_group_label>Type A behaviour profile</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Type B behaviour profile</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample of 12 ml</intervention_name>
    <arm_group_label>Type A behaviour profile</arm_group_label>
    <arm_group_label>Type B behaviour profile</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have provided written informed consent

          -  Patients with type 1 or type 2 diabetes

          -  Patient admitted for a consultation, as out or in-patients to the
             Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU

          -  Patient &gt; 18 years

          -  Patient with either a characteristic Type A behaviour profile (Bortner &gt; 210), or a
             characteristic Type B behaviour profile (Bortner&lt;154)

        Exclusion Criteria:

          -  Persons not covered by national health insurance

          -  Adults under guardianship or wards of court or not intellectually independent

          -  Patients without diabetes

          -  Patients with a mixed A/B behaviour profile (154&lt; Bortner score &lt;210)

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
    <phone>3.80.29.37.69</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
      <phone>3.80.29.37.69</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
